[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2024071480A3 - 금 나노입자를 유효성분으로 포함하는 혈전성 질환의 예방 또는 치료용 조성물 - Google Patents

금 나노입자를 유효성분으로 포함하는 혈전성 질환의 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2024071480A3
WO2024071480A3 PCT/KR2022/014713 KR2022014713W WO2024071480A3 WO 2024071480 A3 WO2024071480 A3 WO 2024071480A3 KR 2022014713 W KR2022014713 W KR 2022014713W WO 2024071480 A3 WO2024071480 A3 WO 2024071480A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
treatment
thrombotic diseases
active ingredient
composition containing
Prior art date
Application number
PCT/KR2022/014713
Other languages
English (en)
French (fr)
Other versions
WO2024071480A2 (ko
Inventor
진철
Original Assignee
진철
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 진철 filed Critical 진철
Priority to PCT/KR2022/014713 priority Critical patent/WO2024071480A2/ko
Publication of WO2024071480A2 publication Critical patent/WO2024071480A2/ko
Publication of WO2024071480A3 publication Critical patent/WO2024071480A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 금 나노입자를 유효성분으로 포함하는 혈전성 질환의 치료 또는 예방용 약학적 조성물에 관한 것이다. 본 발명에서, 상기 금 나노입자는 산화그래핀과 복합체를 형성하고, 상기 복합체는 세포의 세포질 내의 메신저리보핵산(mRNA)과 연결된 후, 세포핵으로 이동되어 상기 mRNA의 표현을 침묵(silencing)시킬 수 있으므로, mRNA 백신에 의해 발생할 수 있는 혈전성 질환 등의 치료 또는 예방에 이용될 수 있다.
PCT/KR2022/014713 2022-09-29 2022-09-29 금 나노입자를 유효성분으로 포함하는 혈전성 질환의 예방 또는 치료용 조성물 WO2024071480A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2022/014713 WO2024071480A2 (ko) 2022-09-29 2022-09-29 금 나노입자를 유효성분으로 포함하는 혈전성 질환의 예방 또는 치료용 조성물

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2022/014713 WO2024071480A2 (ko) 2022-09-29 2022-09-29 금 나노입자를 유효성분으로 포함하는 혈전성 질환의 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
WO2024071480A2 WO2024071480A2 (ko) 2024-04-04
WO2024071480A3 true WO2024071480A3 (ko) 2024-06-27

Family

ID=90478254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/014713 WO2024071480A2 (ko) 2022-09-29 2022-09-29 금 나노입자를 유효성분으로 포함하는 혈전성 질환의 예방 또는 치료용 조성물

Country Status (1)

Country Link
WO (1) WO2024071480A2 (ko)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130130942A (ko) * 2012-05-23 2013-12-03 동국대학교 산학협력단 피브린 표적 펩타이드 서열이 결합된 글라이콜 키토산-금 나노입자를 포함하는 혈전 탐지용 ｃｔ 조영제
KR20160075955A (ko) * 2014-12-19 2016-06-30 중앙대학교 산학협력단 금 나노입자가 도포된 그래핀 옥사이드를 포함하는 pcr 조성물 및 이를 이용한 pcr 방법
KR20170006968A (ko) * 2015-07-10 2017-01-18 경상대학교산학협력단 안토시아닌 및 금 나노입자의 결합체를 포함하는, 퇴행성 뇌질환의 예방 및 치료용 조성물
KR20210087303A (ko) * 2020-01-02 2021-07-12 서강대학교산학협력단 CRISPR/Cas12a를 이용한 표면증강 라만산란 기반 표적 DNA 검출용 센서

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130130942A (ko) * 2012-05-23 2013-12-03 동국대학교 산학협력단 피브린 표적 펩타이드 서열이 결합된 글라이콜 키토산-금 나노입자를 포함하는 혈전 탐지용 ｃｔ 조영제
KR20160075955A (ko) * 2014-12-19 2016-06-30 중앙대학교 산학협력단 금 나노입자가 도포된 그래핀 옥사이드를 포함하는 pcr 조성물 및 이를 이용한 pcr 방법
KR20170006968A (ko) * 2015-07-10 2017-01-18 경상대학교산학협력단 안토시아닌 및 금 나노입자의 결합체를 포함하는, 퇴행성 뇌질환의 예방 및 치료용 조성물
KR20210087303A (ko) * 2020-01-02 2021-07-12 서강대학교산학협력단 CRISPR/Cas12a를 이용한 표면증강 라만산란 기반 표적 DNA 검출용 센서

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LV QINGBO, MA BOXUAN, LI WUJIAO, FU GUOSHENG, WANG XIAOYU, XIAO YUN: "Nanomaterials-Mediated Therapeutics and Diagnosis Strategies for Myocardial Infarction", FRONTIERS IN CHEMISTRY, FRONTIERS MEDIA, LAUSANNE, vol. 10, Lausanne , XP093187751, ISSN: 2296-2646, DOI: 10.3389/fchem.2022.943009 *
XING YUQIAN, HAN JUAN, WU XU, PIERCE DAVID T., ZHAO JULIA XIAOJUN: "Graphene/gold nanoparticle composites for ultrasensitive and versatile biomarker assay using single-particle inductively-coupled plasma/mass spectrometry", ANALYST, ROYAL SOCIETY OF CHEMISTRY, UK, vol. 145, no. 24, 1 January 2020 (2020-01-01), UK , pages 7932 - 7940, XP093187752, ISSN: 0003-2654, DOI: 10.1039/D0AN01019G *

Also Published As

Publication number Publication date
WO2024071480A2 (ko) 2024-04-04

Similar Documents

Publication Publication Date Title
Liu et al. TiO2 nanoparticles cause cell damage independent of apoptosis and autophagy by impairing the ROS-scavenging system in Pichia pastoris
Mohamed et al. Vitamin D3 prevents the deleterious effects of testicular torsion on testis by targeting miRNA-145 and ADAM17: in silico and in vivo study
Yoshioka et al. Allergic responses induced by the immunomodulatory effects of nanomaterials upon skin exposure
CN105263525A (zh) 抗微生物剂的组合物和制剂、它们的方法以及用于治疗微生物感染的方法
PH12014502778B1 (en) Antibody formulation
PH12019550088A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
WO2015152693A3 (ko) 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
EP3158990B1 (en) Formulation for release of nitric oxide
Korting et al. The hydroxypyridones: a class of antimycotics of its own
JP2015523553A5 (ko)
JP2015513359A (ja) 座瘡の排除又は予防用のピルフェニドンと改変ジアリルジスルフィド酸化物（ｍ−ｄｄｏ）とを含む半固形局所組成物
BR112015026053A2 (pt) composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratamento de um paciente sofrendo ou susceptível a sofrer de um distúrbio respiratório e para fabricação de uma composição farmacêutica
EP2705847A8 (en) Composition for treating psoriasis
CN106390130A (zh) 烟酰胺作为抗真菌药物增效剂的用途
WO2024071480A3 (ko) 금 나노입자를 유효성분으로 포함하는 혈전성 질환의 예방 또는 치료용 조성물
Castillo et al. Nanoparticles as new therapeutic agents against Candida albicans
HRP20050917B1 (hr) Postupak za dobivanje kristaliniäśnog ciklesonida s definiranom veliäśinom äśestica
MX2023013972A (es) Compuesto de quinolinamina, metodo de preparacion y aplicacion del mismo en productos farmaceuticos.
JP2017088603A (ja) 膣炎の治療
AU2011274851A1 (en) Particle coating preparation
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
PH12021553055A1 (en) Methods and compositions for improving outcomes of cancer patients
CN105663126B (zh) 盐酸氨溴索联合氟康唑的抗真菌产品及其应用
JP2019055926A (ja) 美白化粧料組成物
MX2022015232A (es) Composicion farmaceutica acuosa de levilimab y su uso.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22959710

Country of ref document: EP

Kind code of ref document: A2